Belgium's Galapagos signs $405 million deal with AbbVie
BRUSSELS (Reuters) - Belgian biotech firm Galapagos GLPG.BR has signed a cooperation deal worth up to $405 million with U.S. company AbbVie to develop a new treatment for cystic fibrosis.
AbbVie will make an upfront payment of $45 million and the Belgian firm is eligible for a further $360 million in additional milestone payments as the project progresses, the companies said on Tuesday.
Because of this announcement, Galapagos increased its 2013 cash balance guidance to 125 million euros from the 100 million euros it had guided for earlier.
Cystic fibrosis, which the companies say affects some 70,000 patients worldwide, is a progressive hereditary disease for which there is currently no cure.
The two companies will build on the research already done by Galapagos and aim to begin the first clinical studies in late 2014.
Before the press release came out, the Belgian market regulator had suspended the shares which were trading 2 percent lower at the time.
On Monday, AbbVie signed a deal with another Belgian biotech group, Ablynx (ABLX.BR), to develop an experimental drug for rheumatoid arthritis.
(Reporting by Robert-Jan Bartunek; Editing by Adrian Croft)
- Sierra Leone's chief Ebola doctor contracts the virus
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- Gaza bloodshed deepens as airlines shun Israel |
- TransAsia Airways plane crashes in typhoon-hit Taiwan, killing 47 |
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand